Cyclerion Therapeutics (CYCN) Income towards Parent Company (2019 - 2025)
Historic Income towards Parent Company for Cyclerion Therapeutics (CYCN) over the last 7 years, with Q3 2025 value amounting to -$1.0 million.
- Cyclerion Therapeutics' Income towards Parent Company changed N/A to -$1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.1 million, marking a year-over-year decrease of 3774.15%. This contributed to the annual value of $7.3 million for FY2023, which is 12837.57% up from last year.
- Latest data reveals that Cyclerion Therapeutics reported Income towards Parent Company of -$1.0 million as of Q3 2025.
- Over the past 5 years, Cyclerion Therapeutics' Income towards Parent Company peaked at $13.5 million during Q3 2023, and registered a low of -$16.2 million during Q2 2021.
- Its 5-year average for Income towards Parent Company is -$6.0 million, with a median of -$5.2 million in 2022.
- Its Income towards Parent Company has fluctuated over the past 5 years, first surged by 32128.43% in 2023, then plummeted by 2080.92% in 2025.
- Cyclerion Therapeutics' Income towards Parent Company (Quarter) stood at -$14.3 million in 2021, then surged by 79.82% to -$2.9 million in 2022, then skyrocketed by 565.74% to $13.5 million in 2023, then plummeted by 110.27% to -$1.4 million in 2024, then rose by 27.31% to -$1.0 million in 2025.
- Its Income towards Parent Company was -$1.0 million in Q3 2025, compared to -$1.7 million in Q2 2025 and -$1.5 million in Q1 2025.